Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 3—March 2020
Research

Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1

Joanne M. LangleyComments to Author , Soren Gantt, Caroline Quach, Julie A. Bettinger, Scott A. Halperin, Jill Mutch, Shelly A. McNeil, Brian J. Ward, Donna MacKinnon-Cameron, Lingyun Ye, Kim Marty, David Scheifele, Erin Brown, Joenel Alcantara, and The Canadian Immunization Research Network
Author affiliations: Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, Nova Scotia, Canada (J.M. Langley, S.A. Halperin, J. Mutch, S.A. McNeil, D. MacKinnon-Cameron, L. Ye); Vaccine Evaluation Center, University of British Columbia, Vancouver, British Columbia, Canada (S. Gantt, J.A. Bettinger, K. Marty, D. Scheifele); University of Montreal, Montreal, Quebec, Canada (C. Quach); Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada (C. Quach, B.J. Ward); University of Calgary, Calgary, Alberta, Canada (E. Brown, J. Alcantara)

Main Article

Table 3

Geometric mean titers of human serum bactericidal antibody to meningococcal B strains in recipients of a longer interval dosing schedule compared with an accelerated dosing schedule in a trial of MenB-4C vaccine, from day 0 to 180 postvaccine, Canada*

MenB strain
 Geometric mean titers (95% CI)
Day 0
 Day 21
 Day 42
 Day 81
 Day 180
5/99
Accelerated 5.86 (4.03–8.54) 63.24 (45.87–87.19) 310.99 (207.74–465.55) 262.30 (183.72–374.50) 114.73 (79.32–165.95)
Longer interval
 9.34 (6.78–12.87)
 74.76 (52.86–105.72)
 162.56 (114.85–230.09)
 482.30 (15.61–737.02)
 144.55 (99.88–209.2)
H44/76
Accelerated 1.50 (1.25–1.80) 34.38 (24.93–47.42) 79.66 (54.86–115.67) 77.75 (54.02– 111.90) 35.7 (24.8– 51.39)
Longer interval
 2.10 (1.66– 2.66)
 27.40 (19.74–38.01)
 22.9 (15.68–33.45)
 85.26 (62.47–116.37)
 23.33 (17.94–3.33)
NZ98/254
Accelerated 3.08 (2.29–413) 32.38 (22.19–47.25) 75.88 (53.30–108.02) 48.98 (33.12–72.43) 25.71 (18.38–35.96)
Longer interval 4.05 (3.00–5.47) 28.06 (20.28–38.82) 25.81 (19.35–34.42) 69.58 (51.27–94.45) 22.22 (16.41–30.09)

*Geometric mean titers of serum bactericidal antibody using human serum as a complement source. 5/99, Neisserial adhesin A surface proteins; H44/76, factor H binding protein; hSBA, human serum bactericidal antibody; MenB, Neisseria meningitidis serotype B; MenB-4C, 4-component protein-based menB; NZ98/254, New Zealand outer membrane vesicle.

Main Article

1Preliminary results from this study were presented at IDWeek, October 26–30, 2016, New Orleans, LA, USA; and at the Meningitis Research Foundation Conference, November 14–15, 2017, London, England, UK.

Page created: February 19, 2020
Page updated: February 19, 2020
Page reviewed: February 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external